Biomea Fusion, Inc. (BMEA) Stock Price & Analysis
Biomea Fusion, Inc. (BMEA) rose 6.28% to USD 2.03 as of September 8, 2026 at 03:29 UTC, according to Nexqual real-time market data.
BMEA last closed at USD 1.91; the session ranged USD 1.89–2.05 on volume of 3,291,010 shares. Market capitalization is $146.77M, with a 52-week range of USD 0.87–2.99 (NMS). Source: Nexqual, September 8, 2026 at 03:29 UTC.
Key Statistics (as of September 8, 2026 at 03:29 UTC)
| Price | USD 2.03 |
|---|---|
| Change | ▲ 6.28% (up) |
| Previous Close | USD 1.91 |
| Open | USD 1.9 |
| Day Range | USD 1.89 – 2.05 |
| 52-Week Range | USD 0.87 – 2.99 |
| Volume | 3,291,010 shares |
| Market Cap | $146.77M |
| Exchange | NMS |
Technical Analysis (BMEA)
Nexqual's technical model rates BMEA "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 03:29 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 80.77 (overbought) |
| vs SMA50 | Above (USD 1.4) |
| MACD | 0.17 (positive) |
Analyst Ratings (BMEA)
Wall Street analysts rate BMEA "Buy" based on 6 analysts, with a mean price target of USD 6.5 (range USD 4–9), per Nexqual as of September 8, 2026 at 03:29 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 6.5 |
| High Target | USD 9 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 6 / 0 / 1 |
Earnings (BMEA)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.22 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.17 vs est -0.23 ▲ beat |
| 2026-03-31 | USD -0.17 vs est -0.19 ▲ beat |
| 2025-12-31 | USD -0.12 vs est -0.22 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.29 ▲ beat |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Financials & Fundamentals (BMEA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -164.14% |
| Debt / Equity | 7.23 |
| Current Ratio | 3.48 |
| Total Cash | $34.82M |
| Total Debt | $877,000 |
| Free Cash Flow | $-27.80M |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Financial Health Score (BMEA)
Nexqual rates Biomea Fusion, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 03:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $35M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$47M |
| Efficiency | Critical — ROE -164%, ROA -63.5% |
Ownership (BMEA)
| Insider Ownership | +7.15% |
|---|---|
| Institutional Ownership | +40.02% |
| Shares Outstanding | 72.30M |
| Float | 67.63M |
| Short % of Float | +16.52% |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Leadership (BMEA)
Biomea Fusion, Inc. is led by Michael J. M. Hitchcock (age 75), Interim CEO & Director, per Nexqual as of September 8, 2026 at 03:29 UTC.
| Interim CEO & Director | Michael J. M. Hitchcock (age 75) |
|---|---|
| Co-Founder, President, COO & Director | Ramses M. Erdtmann (age 62) |
| Senior Vice President of Legal | Caroline Perez- Dupont |
| Executive Vice President of Research | Thorsten Kirschberg (age 55) |
| Executive Vice President of Intellectual Property | Ravi Upasani |
Major Backers & Investors (BMEA)
Notable institutional backers of Biomea Fusion, Inc. include FMR, LLC, Fidelity, Marshall Wace LLP, according to Nexqual as of September 8, 2026 at 03:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.16% |
| Fidelity | 7.4% |
| Marshall Wace LLP | 2.83% |
| Aisling Capital Management LP | 2.83% |
| Renaissance Technologies | 2.01% |
| Fideuram - Intesa Sanpaolo Private Banking S.p.a. | 1% |
| Susquehanna International Group, LLP | 0.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.7% |
| BlackRock | 1.31% |
| Geode Capital | 0.98% |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
From Biomea Fusion, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.
- It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
- The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | USD 43.07 | ▲ 2.6% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.01 | ▼ 3.37% |
| CGEM | Cullinan Therapeutics, Inc. | USD 22.09 | ▼ 1.07% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 14.97 | ▲ 0.2% |
| ANNX | Annexon, Inc. | USD 4.87 | ▼ 1.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 03:29 UTC. This page is informational and not investment advice.